Catalent to offer integrated services in Germany through softgel expansion

Catalent boosts services at Eberbach, Germany site

A coating and packaging expansion at a facility in Germany will feed the demand for end-to-end softgel services, Catalent Pharma Solutions says.

The planned addition of coating and blister packaging equipment is the largest single investment at the 360,000sq ft site in Eberbach, Germany, since Catalent acquired the remaining 49% of drug delivery firm RP Scherer from Gelita in February 2012.

The new equipment will coat softgels for controlled, enteric and targeted release, and push processing output to over 300 million capsules per year and, according to Richard Lackner, General Manager at the Eberbach plant, is a “timely” investment for the contract development and manufacturing organization (CDMO).

“As more customers look for integrated services from a single, convenient site, Catalent’s investment in softgel coating and packaging is timely,” he told this publication.

“Its integrated, same-site softgel manufacturing and coating services enhance process efficiency and control, minimizing the time between encapsulation and coating, and therefore, maximizing product shelf life,” he continued, adding “Catalent will soon be able to provide end-to-end service to its customers from the Eberbach site, from development to shelf-ready.”

Financial details of the expansion were not revealed and Lackner did not foresee a large number of new jobs being created in Eberbach, but the investment is evidence of Catalent’s continued advancement of its drug delivery systems, he said, which, since the closing of the RP Scherer deal, has seen it offer oral delivery of macromolecules through its OptiGel platform, as well as offer new anti-abuse encapsulating technology.

Driven by Innovation

As for market demand, Jessica Cao, Strategic Marketing Director for Softgel Technologies at Catalent, told us it the firm is seeing increased growth “driven by innovation in formulation, especially lipid-based formulations, including delivery of highly potent compounds, to overcome the bioavailability challenges of delivering poorly soluble drugs, and for modified and controlled release.”

In September, Catalent reported its end of year financials and its growth in revenue was primarily led by its softgel business.

The firm has recently invested in China and Brazil in order to support its softgel network, and Cao said its supply network now consists of 11 softgel R&D and manufacturing sites with the capacity to produce over 60 billion capsules annually.

Related News

Post-IPO Catalent turns to internal investments to meet new demands

Post-IPO Catalent turns to internal investments to meet new demands

Capsugel invests in vegetarian capsules

Capsugel invests in vegetarian capsules citing demand for lower moisture content and API cross-linking risk

Expanded Catalent Pharma Solutions site in Winchester Kentucky

Catalent completes expansion of US complex tablet site

Image: iStock/DigtialStorm

Catalent continues to scout acquisitions and licensing in 2016

Image: iStock

Blu buy bolsters Puracap in US softgel market

Image: iStock/Viperfzk

Catalent's oral biz hit by Beinheim suspension and low modified release demand

Source Google images

Catalent to plug bioavailability tech gap with Pharmatek Laboratories buy

Images: iStcok/emiliozv

Catalent to assess resveratrol formulation across softgel platforms

Catalent Completes Chinese Softgel Acquisition

Catalent Completes Chinese Softgel Acquisition

Capsule talks softegl tech at CPhI Frankfurt

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent purchases Brazilian softgel firm Relthy Labs

Catalent's Brazilian acquisition supports global softgel strategy

Catalent bringing in the closing of the New York Stock Exchange on Monday.

Catalent sees growth strengthened by international softgel markets

Related Products

See more related products